Physician profile
Kate Mccabe
NPI 1730735010
$10,652.18
in general payments reported to CMS, 2019-2025
26 companies · $2,208 in 2025
The $2,208 reported for 2025 was more than what 96% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,171 · 2022: $2,062 · 2023: $2,464 · 2024: $1,747 · 2025: $2,208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,262 · Education: $157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,262.38 |
| Education | $156.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,725.18 | 2021-2025 | Tremfya, Stelara, Simponi |
| Genzyme Corporation | $1,110.52 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $971.07 | 2022-2025 | Sotyktu, Sprycel |
| Novartis Pharmaceuticals Corporation | $957.56 | 2021-2025 | |
| Abbvie INC. | $892.86 | 2021-2025 | |
| Amgen INC. | $682.46 | 2021-2025 | Otezla, Otezla, Enbrel |
| Lilly USA, LLC | $629.30 | 2021-2025 | Olumiant, Taltz, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $552.31 | 2021-2025 | Libtayo |
| Sun Pharmaceutical Industries INC. | $509.75 | 2021-2025 | Ilumya, Absorica Ld, Winlevi |
| Incyte Corporation | $484.81 | 2021-2025 | Opzelura |
| Ucb, INC. | $471.70 | 2021-2025 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $385.99 | 2021-2025 | Nemluvio, Aklief |
| Janssen Scientific Affairs, LLC | $233.78 | 2021 | |
| Arcutis Biotherapeutics, INC. | $230.59 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $132.72 | 2022-2024 | Vtama |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $125.80 | 2025 | Vtama |
| Takeda Pharmaceuticals U.S.A., INC. | $123.96 | 2024 | Entyvio |
| Botanix Sb INC | $115.10 | 2025 | Sofdra |
| Pfizer INC. | $86.66 | 2021-2023 | |
| Leo Pharma INC. | $78.95 | 2022-2023 | Adbry |
| Fresenius Kabi USA, LLC | $34.45 | 2023 | Idacio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.22 | 2022 | |
| Celgene Corporation | $26.21 | 2024 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $24.00 | 2021 | |
| Vyne Pharmaceuticals INC. | $21.44 | 2021 | |
| Biofrontera INC. | $16.79 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kate Mccabe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.